Lingtao Peng

Title: Innovations of Lingtao Peng in Genetic Therapy

Introduction

Lingtao Peng is an accomplished inventor based in Boston, MA (US). He has made significant contributions to the field of genetic therapy, particularly in the treatment of retinal disorders. His innovative work focuses on developing nucleic acid trans-splicing molecules that can correct mutations in the ABCA4 gene.

Latest Patents

Lingtao Peng holds a patent for ABCA4 trans-splicing molecules. This patent describes nucleic acid trans-splicing molecules, including pre-mRNA trans-splicing molecules and RNA exon editing molecules. These molecules are designed to correct mutations in the ABCA4 gene, which is associated with disorders such as Stargardt Disease and cone-rod dystrophy. The patent outlines methods for using these molecules to treat disorders linked to mutations in ABCA4, as well as their application in preparing medicaments for such treatments.

Career Highlights

Lingtao Peng is currently associated with Ascidian Therapeutics, Inc., where he continues to advance his research in genetic therapies. His work has the potential to significantly impact the treatment of genetic disorders, providing hope for patients affected by these conditions.

Collaborations

Lingtao collaborates with notable colleagues, including Rebekka Krumbach and Scott J Dooley. Their combined expertise enhances the research and development efforts at Ascidian Therapeutics, Inc.

Conclusion

Lingtao Peng's innovative contributions to genetic therapy, particularly through his patent on ABCA4 trans-splicing molecules, highlight his role as a leading inventor in the field. His work promises to pave the way for new treatments for retinal disorders, showcasing the importance of innovation in medical science.